-
2
-
-
80052031181
-
Comparative performance of the new versus old FIGO staging system for endometrial cancer
-
Lewin S, Herzog T, Barrena Medel N, et al. Comparative performance of the new versus old FIGO staging system for endometrial cancer. Gynecol Oncol. 2010;116:S6-7.
-
(2010)
Gynecol Oncol.
, vol.116
-
-
Lewin, S.1
Herzog, T.2
Barrena Medel, N.3
-
3
-
-
79955665860
-
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
-
doi: 10.1002/14651858.CD007697.pub2
-
Ang C, Chan KKL, Bryant A, et al. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(4):CD007697. doi: 10.1002/14651858.CD007697.pub2.
-
(2011)
Cochrane Database Syst Rev
, Issue.4
-
-
Ang, C.1
Chan, K.K.L.2
Bryant, A.3
-
5
-
-
33846457870
-
Cancer statistics, 2007
-
17237035 10.3322/canjclin.57.1.43
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
-
(2007)
CA Cancer J Clin.
, vol.57
, Issue.1
, pp. 43-66
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
6
-
-
27744551640
-
2004 Consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
-
16239238 10.1093/annonc/mdi961
-
du Bois A, Quinn M, Thigpen T, et al. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 (Suppl 8):viii7-12.
-
(2005)
Ann Oncol
, vol.16
, Issue.SUPPL. 8
-
-
Du Bois, A.1
Quinn, M.2
Thigpen, T.3
-
7
-
-
30044438368
-
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
-
16394300 10.1056/NEJMoa052985 1:CAS:528:DC%2BD28XhvV2qsQ%3D%3D
-
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
-
(2006)
N Engl J Med.
, vol.354
, Issue.1
, pp. 34-43
-
-
Armstrong, D.K.1
Bundy, B.2
Wenzel, L.3
-
8
-
-
29144462090
-
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study
-
16368440 10.1016/j.ygyno.2005.11.013
-
Walker J, Armstrong DK, Huang HK, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;100(1):27-32.
-
(2006)
Gynecol Oncol.
, vol.100
, Issue.1
, pp. 27-32
-
-
Walker, J.1
Armstrong, D.K.2
Huang, H.K.3
-
9
-
-
0141688377
-
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
-
12860964 10.1200/JCO.2003.02.153 1:CAS:528:DC%2BD2cXps1aktbk%3D
-
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21 (17):3194-200.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.17
, pp. 3194-3200
-
-
Ozols, R.F.1
Bundy, B.N.2
Greer, B.E.3
-
10
-
-
0028107944
-
A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer
-
8088611 10.1006/gyno.1994.1220 1:STN:280:DyaK2cznsVOktQ%3D%3D
-
Kirmani S, Braly PS, McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol. 1994;54 (3):338-44.
-
(1994)
Gynecol Oncol.
, vol.54
, Issue.3
, pp. 338-344
-
-
Kirmani, S.1
Braly, P.S.2
McClay, E.F.3
-
11
-
-
79957759352
-
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group study
-
21497382 10.1016/j.ygyno.2011.03.036 1:CAS:528:DC%2BC3MXmslOgu78%3D
-
Coleman, Brady, McMeekin, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122 (1):111-5.
-
(2011)
Gynecol Oncol.
, vol.122
, Issue.1
, pp. 111-115
-
-
Coleman1
Brady2
McMeekin3
-
12
-
-
80052966711
-
Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis
-
21843904 10.1016/j.biomaterials.2011.07.067 1:CAS:528:DC%2BC3MXhtFOlsrrI
-
Werner ME, Karve S, Sukumar R, et al. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011;32 (33):8548-54.
-
(2011)
Biomaterials.
, vol.32
, Issue.33
, pp. 8548-8554
-
-
Werner, M.E.1
Karve, S.2
Sukumar, R.3
-
13
-
-
79955012698
-
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles
-
21371545 10.1016/j.ijpharm.2011.02.037 1:CAS:528:DC%2BC3MXkslektro%3D
-
Sloat BR, Sandoval MA, Li D, et al. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm. 2011;409 (1-2):278-88.
-
(2011)
Int J Pharm.
, vol.409
, Issue.1-2
, pp. 278-288
-
-
Sloat, B.R.1
Sandoval, M.A.2
Li, D.3
-
14
-
-
84934442494
-
Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy
-
18546630 10.1007/978-0-387-68969-2-17 1:CAS:528:DC%2BC3cXhtlKisb3P
-
Sawicki JA, Anderson DG, Langer R. Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy. Adv Exp Med Biol. 2008;622:209-19.
-
(2008)
Adv Exp Med Biol.
, vol.622
, pp. 209-219
-
-
Sawicki, J.A.1
Anderson, D.G.2
Langer, R.3
-
15
-
-
81855180822
-
Paclitaxel-loaded expansile nanoparticles in a multimodal treatment model of malignant mesothelioma
-
21963198 10.1016/j.athoracsur.2011.04.106
-
Schulz MD, Zubris KA, Wade JE, et al. Paclitaxel-loaded expansile nanoparticles in a multimodal treatment model of malignant mesothelioma. Ann Thorac Surg. 2011;92 (6):2007-13.
-
(2011)
Ann Thorac Surg.
, vol.92
, Issue.6
, pp. 2007-2013
-
-
Schulz, M.D.1
Zubris, K.A.2
Wade, J.E.3
-
16
-
-
67749143922
-
Expansile nanoparticles: Synthesis, characterization, and in vivo efficacy of an acid responsive polymeric drug delivery system
-
19182897 10.1021/ja807416t 1:CAS:528:DC%2BD1MXhtlensbk%3D
-
Griset AP, Walpole J, Liu R, et al. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid responsive polymeric drug delivery system. J Am Chem Soc. 2009;131:2469-71.
-
(2009)
J Am Chem Soc.
, vol.131
, pp. 2469-2471
-
-
Griset, A.P.1
Walpole, J.2
Liu, R.3
-
17
-
-
0021683409
-
Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice
-
6333272 1:CAS:528:DyaL2cXmt1Oqsrk%3D
-
Hamilton TC, Young RC, Louie KG, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 1984;44:5286-90.
-
(1984)
Cancer Res.
, vol.44
, pp. 5286-5290
-
-
Hamilton, T.C.1
Young, R.C.2
Louie, K.G.3
-
18
-
-
0024435434
-
Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy
-
2777413 10.1002/ijc.2910440320 1:STN:280:DyaL1MznvFCmsw%3D%3D
-
Massazza G, Tomasoni A, Lucchini V, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer. 1989;44:494-500.
-
(1989)
Int J Cancer.
, vol.44
, pp. 494-500
-
-
Massazza, G.1
Tomasoni, A.2
Lucchini, V.3
-
19
-
-
35948943122
-
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group
-
17975154 10.1158/1078-0432.CCR-07-0064 1:CAS:528:DC%2BD2sXht1CgtbzP
-
Joerger M, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res. 2007;13:6410.
-
(2007)
Clin Cancer Res.
, vol.13
, pp. 6410
-
-
Joerger, M.1
-
20
-
-
0035189634
-
Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer
-
11146078 10.1016/S0020-7292(00)00340-4 1:CAS:528:DC%2BD3MXnvFyn
-
Yen MS, Juang CM, Lai CR, et al. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet. 2001;72 (1):55-60.
-
(2001)
Int J Gynaecol Obstet.
, vol.72
, Issue.1
, pp. 55-60
-
-
Yen, M.S.1
Juang, C.M.2
Lai, C.R.3
-
21
-
-
77957746020
-
A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer [abstract]
-
Konner JA, Grabon D, Pezzulli S, et al. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer [abstract]. J Clin Oncol. 2009;27:5539.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 5539
-
-
Konner, J.A.1
Grabon, D.2
Pezzulli, S.3
-
22
-
-
0028237380
-
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
-
Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170 (4):974-9.
-
(1994)
Am J Obstet Gynecol
, vol.170
, Issue.4
, pp. 974-979
-
-
Hoskins, W.J.1
McGuire, W.P.2
Brady, M.F.3
-
23
-
-
0026620239
-
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study
-
1468693 10.1016/0090-8258(92)90100-W 1:STN:280:DyaK3s7gs1Cqsw%3D%3D
-
Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47 (2):159-66.
-
(1992)
Gynecol Oncol.
, vol.47
, Issue.2
, pp. 159-166
-
-
Hoskins, W.J.1
Bundy, B.N.2
Thigpen, J.T.3
-
24
-
-
0036498788
-
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
-
11870167 10.1200/JCO.20.5.1248
-
Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20 (5):1248-59.
-
(2002)
J Clin Oncol.
, vol.20
, Issue.5
, pp. 1248-1259
-
-
Bristow, R.E.1
Tomacruz, R.S.2
Armstrong, D.K.3
-
25
-
-
0345280812
-
Influence of the surfactant concentration on the body distribution of nanoparticles
-
10.3109/10611869908996844 1:CAS:528:DyaK1MXjtlCgsLw%3D
-
Araujo L, Lobenberg R, Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J Drug Targeting. 1999;6:373-85.
-
(1999)
J Drug Targeting.
, vol.6
, pp. 373-385
-
-
Araujo, L.1
Lobenberg, R.2
Kreuter, J.3
-
26
-
-
33750218653
-
A phase i trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: A Gynecologic Oncology Group study
-
16626792 10.1016/j.ygyno.2006.02.029 1:CAS:528:DC%2BD28XhtFegtbvF
-
Armstrong DK, Fleming GF, Markman M, Bailey HH. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;103:391-6.
-
(2006)
Gynecol Oncol.
, vol.103
, pp. 391-396
-
-
Armstrong, D.K.1
Fleming, G.F.2
Markman, M.3
Bailey, H.H.4
-
27
-
-
84855467144
-
Hydrogels as intracellular depots for drug delivery
-
22053709 10.1021/mp200367s 1:CAS:528:DC%2BC3MXhsVWmsrnJ
-
Zubris KA, Colson YL, Grinstaff MW. Hydrogels as intracellular depots for drug delivery. Mol Pharm. 2012;9(1):196-200.
-
(2012)
Mol Pharm.
, vol.9
, Issue.1
, pp. 196-200
-
-
Zubris, K.A.1
Colson, Y.L.2
Grinstaff, M.W.3
-
28
-
-
48349107149
-
Tumour-targeted nanomedicines: Principles and practice
-
18648371 10.1038/sj.bjc.6604483 1:CAS:528:DC%2BD1cXptFSntr0%3D
-
Lammers T, Hannink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99(3):392-7.
-
(2008)
Br J Cancer.
, vol.99
, Issue.3
, pp. 392-397
-
-
Lammers, T.1
Hannink, W.E.2
Storm, G.3
-
29
-
-
36849067019
-
Nanocarriers as an emerging platform for cancer therapy
-
18654426 10.1038/nnano.2007.387 1:CAS:528:DC%2BD2sXhtlyktL%2FI
-
Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-60.
-
(2007)
Nat Nanotechnol.
, vol.2
, pp. 751-760
-
-
Peer, D.1
Karp, J.M.2
Hong, S.3
-
30
-
-
78650196945
-
Nanomedicine
-
21158659 10.1056/NEJMra0912273 1:CAS:528:DC%2BC3cXhsF2ltb7E
-
Kim BY, Rutka JT, Chan WC, et al. Nanomedicine. N Engl J Med. 2010;363:2434-43.
-
(2010)
N Engl J Med.
, vol.363
, pp. 2434-2443
-
-
Kim, B.Y.1
Rutka, J.T.2
Chan, W.C.3
-
31
-
-
79960901684
-
Tumor targeted nanoparticles: A modern day Trojan horse
-
21807291 10.1053/j.semtcvs.2011.03.004
-
Gilmore D, Colson YL. Tumor targeted nanoparticles: a modern day Trojan horse. Semin Thorac Cardiovasc Surg. 2011;23(1):10-11.
-
(2011)
Semin Thorac Cardiovasc Surg.
, vol.23
, Issue.1
, pp. 10-11
-
-
Gilmore, D.1
Colson, Y.L.2
-
32
-
-
0021965064
-
White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis
-
3967867 10.1002/hep.1840050118 1:STN:280:DyaL2M7gtlakug%3D%3D
-
Yang CY, Liaw YF, Chu CM, Sheen IS. White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis. Hepatology. 1985;5(1):85-90.
-
(1985)
Hepatology.
, vol.5
, Issue.1
, pp. 85-90
-
-
Yang, C.Y.1
Liaw, Y.F.2
Chu, C.M.3
Sheen, I.S.4
-
34
-
-
0021732164
-
The relevance of tumour pH to the treatment of malignant disease
-
6097949 10.1016/S0167-8140(84)80077-8 1:STN:280:DyaL2M7hsVWjuw%3D%3D
-
Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol. 1984;2:343-66.
-
(1984)
Radiother Oncol.
, vol.2
, pp. 343-366
-
-
Wike-Hooley, J.L.1
Haveman, J.2
Reinhold, H.S.3
-
35
-
-
0026795032
-
Regulation of intracellular pH in tumor cell lines: Influence of microenvironmental conditions
-
1322790 1:CAS:528:DyaK38Xls1ylt7g%3D
-
Boyer MJ, Tannock IF. Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res. 1992;52:4441-7.
-
(1992)
Cancer Res.
, vol.52
, pp. 4441-4447
-
-
Boyer, M.J.1
Tannock, I.F.2
|